[144] Esperion Therapeutics, Inc. SEC Filing
Rhea-AI Filing Summary
Esperion Therapeutics (ESPR) Form 144 notice: The filer reports a proposed sale of 6,267 common shares with an aggregate market value of $17,575.80, to be sold through Fidelity Brokerage Services LLC on or about 09/17/2025 on the NASDAQ. The shares were acquired on 09/15/2025 by restricted stock vesting from the issuer and were paid as compensation. The filing also discloses sales by the same person in the prior three months: 6,422 shares sold on 06/17/2025 for $7,397.50 and 1,304 shares sold on 07/17/2025 for $1,469.35. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information.
Positive
- Full compliance with Rule 144 disclosure requirements including broker, acquisition details, and prior three-month sales
- Clear attribution of shares as restricted stock vesting and payment as compensation, providing transparency on origin of securities
Negative
- Insider selling activity disclosed: proposed sale of 6,267 shares and prior sales totaling 7,726 shares in the past three months
Insights
TL;DR: Insider proposes to sell 6,267 newly vested restricted shares; prior small sales occurred in June and July.
The filing documents a proposed sale of 6,267 common shares acquired by restricted stock vesting on 09/15/2025 with an aggregate market value of $17,575.80, to be executed via Fidelity on or about 09/17/2025. The filer also reported two prior sales in the last three months totaling 7,726 shares with combined gross proceeds of $8,866.85. All details presented are transactional: acquisition method is explicitly listed as restricted stock vesting and payment as compensation. No financial results, forward guidance, or other issuer-level metrics are included in this notice.
TL;DR: Routine Rule 144 disclosure of vested equity being offered for sale; contains required seller attestation.
The notice fulfills Rule 144 reporting by identifying the class, quantity, acquisition date, acquisition nature (restricted stock vesting), broker, and approximate sale date. It includes the seller's attestation regarding material nonpublic information and a signature block warning about false statements. The filing is procedural and does not disclose any additional governance actions or extraordinary transactions.